MedTrace Logo

Long-term Monitoring of Patients With Cardiac Amyloidosis With Implantable Event Monitors

NCT04421040 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2024-04-16

Study results available
· View outcomes & findings →

Summary

Researchers are gathering information to see if using an FDA approved implantable device can help with monitoring of your heart arrhythmias.

Conditions

  • TTR Cardiac Amyloidosis

Interventions

DEVICE

Biotronik Biomonitor 3 implant of device

The Biotronik Biomonitor 3 device will be implanted by the research team physician.

DEVICE

Biotronik Biomonitor 3 explant of device

The Biotronik Biomonitor 3 device will be removed from the patient by the research team physician.

Sponsors & Collaborators

Principal Investigators

  • Omar Abou Ezzeddine, MD, MS · Mayo Clinic

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-07
Primary Completion
2023-03-22
Completion
2023-03-22
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04421040 on ClinicalTrials.gov